References
Akin S, Gucuk-Ipek E, Hayta U, et al. Long-term dexamethasone treatment increases cardiac galectin-3 levels. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07344-w.
Ospina-Quintero L, Jaramillo JC, Tabares-Guevara JH, Ramírez-Pineda JR. Reformulating small molecules for cardiovascular disease immune intervention: low-dose combined vitamin D/dexamethasone promotes IL-10 production and atheroprotection in dyslipidemic mice. Front Immunol. 2020;11:743.
Wang H, Yao X, Huang K, et al. Low-dose dexamethasone in combination with luteolin improves myocardial infarction recovery by activating the antioxidative response. Biomed Pharmacother. 2022;151:113121.
Tao Z, Loo S, Su L, et al. Dexamethasone inhibits regeneration and causes ventricular aneurysm in the neonatal porcine heart after myocardial infarction. J Mol Cell Cardiol. 2020;144:15–23.
de Salvi GF, de Moraes WM, Bozi LH, et al. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Mol Cell Biochem. 2017;424(1-2):87–98.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interests
The authors report no relationships that could be construed as a conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Han, QF., Liu, JH. & Mo, DG. The Effects of Dexamethasone on Cardiovascular Disease: Friend or Foe?. Cardiovasc Drugs Ther 37, 847–848 (2023). https://doi.org/10.1007/s10557-022-07375-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-022-07375-3